An interventional study of Colesevelam HCl and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by KineMed. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-01-17.
Sponsored by KineMed · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 123rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 22 with no phase, and was the 86th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
KineMed is the lead sponsor of 5 studies on the registry; none are open to participants now.
KineMed has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise
The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in HbA1c compared to colesevelam HCl treatment by
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Drug: Colesevelam HCl
Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Drug: Colesevelam HCl · Drug: Sitagliptin
Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Also known as: Welchol
Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Also known as: Januvia
Hemoglobin A1C
Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments
Time frame: Baseline and 12 weeks
Fasting Plasma Glucose
Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.
Time frame: Baseline and 12 weeks
Fasting Endogenous Glucose Production
Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time frame: baseline and 12 weeks
Fasting Gluconeogenesis
Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time frame: baseline and 12 weeks
Fasting Glycogenolysis
Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time frame: baseline and 12 weeks
Fasting Plasma Glucose Clearance
Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.
Time frame: baseline and 12 weeks
Appearance Rate of Oral Glucose
Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments
Time frame: baseline and 12 weeks
Postprandial Endogenous Glucose Production
Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.
Time frame: baseline and 12 weeks
Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)
Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.
Time frame: baseline and 12 weeks
Whole-body Glycolytic Disposal of Oral Glucose
Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments
Time frame: baseline and 12 weeks
Postprandial Glucose (AUC)
Comparison between baseline and 12 weeks values of postrandial glucose (AUC).
Time frame: Baseline and 12 weeks
Fasting Plasma C-peptide
To evaluate the effect of treatments on plamsa C-peptide concentrations.
Time frame: Baseline and 12 weeks
Fasting Plamsa Glucagon
To evaluate the effect of treatments on plasma glucagon concentrations.
Time frame: Baseline and 12 weeks
Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)
To evaluate the effect of treatments on plasma GLP-1 concentrations.
Time frame: Baseline and 12 weeks
Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)
To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.
Time frame: Baseline and 12 weeks
Fasting Insulin
To evaluate the effect of treatments on fasting insulin concentrations
Time frame: Baseline and 12 weeks
Postprandial Insulin (AUC)
To evaluate the effect of treatments on postprandial insulin (AUC)
Time frame: Baseline and 12 weeks
Postprandial C-peptide (AUC)
To evaluate the effect of treatments on postprandial C-peptide (AUC)
Time frame: Baseline and 12 weeks
Postprandial Active GLP-1 (AUC)
To evaluate the effects of treatments on postprandial active GLP-1 (AUC)
Time frame: Baseline and 12 weeks
Postprandial Total GIP (AUC)
To evaluate the effects of treatment on postprandial total GIP (AUC)
Time frame: Baseline and 12 weeks
Postprandial Glucagon (AUC)
To evaluate the effects of treatment on postprandial glucagon (AUC)
Time frame: Baseline and 12 weeks
Study period from February 2010 to December 2010. This was a multi-center, randomized, open-label, prospective, parallel-group study consisting of 12 weeks of active treatment.
| Milestone | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Started | 31 | 30 |
| Completed | 24 | 26 |
| Not completed | 7 | 4 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Glucose >300mg/dl | 1 | 0 |
| Withdrew: High fasting triglyceride | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments
| percentage | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Hemoglobin A1C | 0.3 ± 1.2 | -0.1 ± 1.1 |
To evaluate the effect of treatments on plamsa C-peptide concentrations.
| picomoles (pmol)/Liter (L) | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Plasma C-peptide | 26 ± 217 | 103 ± 195 |
Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.
| millimoles (mmol)/Liter (L) | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Plasma Glucose | -0.8 ± 2.1 | -0.6 ± 2.3 |
To evaluate the effect of treatments on plasma glucagon concentrations.
| picograms (pg)/milliliter (ml) | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Plamsa Glucagon | 1 ± 22 | 0 ± 17 |
To evaluate the effect of treatments on plasma GLP-1 concentrations.
| pmol/L | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1) | 2.4 ± 4.2 | 2.8 ± 8.4 |
To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.
| pmol/L | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP) | 1.8 ± 8.5 | -1.3 ± 3.4 |
Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
| micromoles (umol) per kg FFM per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Endogenous Glucose Production | 1.0 ± 4.4 | 1.0 ± 3.3 |
Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
| umol per kilogram (kg) FFM per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Gluconeogenesis | 0.2 ± 1.5 | -0.3 ± 1.3 |
Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
| umol per kg Fat-Free Mass (FFM) per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Glycogenolysis | 0.8 ± 3.6 | 1.7 ± 3.0 |
Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.
| ml per kg FFM per minute (min) | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Plasma Glucose Clearance | 0.30 ± 0.35 | 0.27 ± 0.41 |
Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments
| umol per kg per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Appearance Rate of Oral Glucose | 118 ± 613 | -244 ± 464 |
Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.
| umol per kg per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Endogenous Glucose Production | -0.1 ± 2.0 | -0.2 ± 1.5 |
Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.
| umol per kg per min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC) | -10 ± 914 | -256 ± 627 |
Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments
| Percent of Load | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Whole-body Glycolytic Disposal of Oral Glucose | 4 ± 6 | 2 ± 6 |
Comparison between baseline and 12 weeks values of postrandial glucose (AUC).
| millimoles (mmol)/l x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Glucose (AUC) | -1.1 ± 2.6 | -1.5 ± 2.8 |
To evaluate the effect of treatments on fasting insulin concentrations
| pmol/L | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Fasting Insulin | 6 ± 38 | 12 ± 36 |
To evaluate the effect of treatments on postprandial insulin (AUC)
| pmol/l x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Insulin (AUC) | -13 ± 118 | 40 ± 73 |
To evaluate the effect of treatments on postprandial C-peptide (AUC)
| pmol/l x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial C-peptide (AUC) | 30 ± 390 | 193 ± 367 |
To evaluate the effects of treatments on postprandial active GLP-1 (AUC)
| pmol/l x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Active GLP-1 (AUC) | 1.8 ± 7.9 | 6.6 ± 4.9 |
To evaluate the effects of treatment on postprandial total GIP (AUC)
| pmol/l x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Total GIP (AUC) | -2 ± 6 | -5 ± 7 |
To evaluate the effects of treatment on postprandial glucagon (AUC)
| picograms (pg)/milliter (ml) x min | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Postprandial Glucagon (AUC) | -7 ± 15 | -4.7 ± 11 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Colesevelam | — | 0/31 (0%) | 1/31 (3.2%) |
| Colesevelam Plus Sitagliptin | — | 0/30 (0%) | 1/30 (3.3%) |
| Event | Colesevelam | Colesevelam Plus Sitagliptin |
|---|---|---|
| Non-related Adverse EventGeneral disorders | 0/31 | 1/30 |
| Tingling sensation in lower extremitiesNervous system disorders | 1/31 | 0/30 |
| Age, Categorical(Participants) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 21 | 45 |
| >=65 years | 7 | 9 | 16 |
| Age Continuous(years) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| Mean | 56 ± 9 | 55 ± 13 | 55.5 ± 11 |
| Sex: Female, Male(Participants) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| Female | 12 | 14 | 26 |
| Male | 19 | 16 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| Hispanic or Latino | 30 | 29 | 59 |
| Not Hispanic or Latino | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 26 | 27 | 53 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| United States | 31 | 30 | 61 |
| Weight(kilograms) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| Mean | 84.6 ± 15.3 | 85.1 ± 17.0 | 84.85 ± 16.15 |
| BMI(kilograms/square meter (kg/m2)) | Colesevelam | Colesevelam Plus Sitagliptin | Total |
|---|---|---|---|
| Mean | 30.7 ± 3.7 | 30.9 ± 4.7 | 30.8 ± 4.2 |
10 further baseline measures are reported on the registry.
The record gives a start of Mar 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin
KineMed